Skip to main content
Premium Trial:

Request an Annual Quote

Syapse to Provide Computational Support for Drug Repositioning and Development Alliance

Premium

Palo Alto, Calif.–based Syapse said this week that it semantic computing platform and application suite will be to develop GaugeRx, a web-based analytics and assessment tool that will use human health and disease information to support drug repositioning and development.

GaugeRx, which will be launched at the end of 2013, is being developed as part of a collaboration between Switzerland's EspeRare Foundation and the United States' Genetic Alliance.

The partners plan to build a tool that provides pharmaceutical companies among others with information that will help them use existing resources and prioritize programs that advance their drug research and development portfolios.

GaugeRx will incorporate data from the Genetic Alliance's Navigating the Ecosystem of Translational Science system which provides a drug development map, and from its Disease InfoSearch resource, a curated compendium of data on genetic conditions. It will use Syapse's platform to handle data and knowledge management, mining, and reporting.

The financial details of the agreement were not disclosed.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.